Marinus Pharmaceuticals Comments On Ovid Therapeutics' Patent Challenge And Provides Update On Marinus' Post Grant Review
Marinus Pharmaceuticals Comments On Ovid Therapeutics' Patent Challenge And Provides Update On Marinus' Post Grant Review
Marinus Pharmicals對Ovid Therapeutics的專利質疑發表評論並提供了Marinus撥款後審查的最新情況
affirmed its commitment to defending its patent portfolio amidst an Inter Partes Review (IPR) challenge of U.S. Patent 11,110,100 from Ovid Therapeutics, Inc. filed on March 26, 2024. This challenge relates to a Marinus patent for the use of ganaxolone in treating status epilepticus (SE) and refractory status epilepticus (RSE). Marinus has multiple patents relating to ganaxolone for the treatment of SE and RSE.
在對Ovid Therapeutics, Inc.於2024年3月26日提交的美國專利11,110,100項的跨方審查（IPR）質疑中，重申了其捍衛其專利組合的承諾。這項挑戰與馬里納斯關於使用加那索龍治療癲癇持續狀態（SE）和難治性癲癇持續狀態（RSE）的專利有關。Marinus擁有多項與用於治療SE和RSE的加那索隆相關的專利。